Abstract
Tuberculosis (TB) caused by Mycobacterium tuberculosis claims millions of lives each year globally. Although it can be controlled by currently available drug regimen (DOTS), yet the emergence of multidrug resistance (MDR) and extensively drug resistance (XDR) TB is a growing concern. The increasing rate of MDR-TB, co-infection with HIV and XDR-TB necessitates the development of new anti-TB agents that have a practical impact on tuberculosis control. This review article gives a brief introduction of tuberculosis, present day problems, traditional and new anti-TB drug targets, currently used drugs, their mode of action, the pipeline compounds and a short description of new chemical entities (NCEs) as antitubercular agents developed in last 10 years.
Keywords: Antitubercular agents, Arabinogalactan, Chemotherapy, Extensively Drug Resistance (XDR), Fatty acid synthase, MultiDrug Resistance (MDR), Mycobacterium tuberculosis, Mycolic acid, Peptidoglycan, Tuberculosis (TB)
Current Medicinal Chemistry
Title: Developments in Chemical Approaches to Treat Tuberculosis in the Last Decade
Volume: 19 Issue: 4
Author(s): R. P. Tripathi, S. S. Bisht, A. Ajay, A. Sharma, M. Misra and M. Pd. Gupt
Affiliation:
Keywords: Antitubercular agents, Arabinogalactan, Chemotherapy, Extensively Drug Resistance (XDR), Fatty acid synthase, MultiDrug Resistance (MDR), Mycobacterium tuberculosis, Mycolic acid, Peptidoglycan, Tuberculosis (TB)
Abstract: Tuberculosis (TB) caused by Mycobacterium tuberculosis claims millions of lives each year globally. Although it can be controlled by currently available drug regimen (DOTS), yet the emergence of multidrug resistance (MDR) and extensively drug resistance (XDR) TB is a growing concern. The increasing rate of MDR-TB, co-infection with HIV and XDR-TB necessitates the development of new anti-TB agents that have a practical impact on tuberculosis control. This review article gives a brief introduction of tuberculosis, present day problems, traditional and new anti-TB drug targets, currently used drugs, their mode of action, the pipeline compounds and a short description of new chemical entities (NCEs) as antitubercular agents developed in last 10 years.
Export Options
About this article
Cite this article as:
P. Tripathi R., S. Bisht S., Ajay A., Sharma A., Misra M. and Pd. Gupt M., Developments in Chemical Approaches to Treat Tuberculosis in the Last Decade, Current Medicinal Chemistry 2012; 19(4) . https://dx.doi.org/10.2174/092986712798918815
DOI https://dx.doi.org/10.2174/092986712798918815 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Innate Immunity, Toll-Like Receptors, and Diabetes
Current Immunology Reviews (Discontinued) Novel Research Strategies of Benzimidazole Derivatives: A Review
Mini-Reviews in Medicinal Chemistry Epidemiology of HIV Infection in Women and Children: A Global Perspective
Current HIV Research An Improved Computational Prediction Model for Lysine Succinylation Sites Mapping on Homo sapiens by Fusing Three Sequence Encoding Schemes with the Random Forest Classifier
Current Genomics Penicillium marneffei and its Pulmonary Involvements
Current Respiratory Medicine Reviews Single Nucleotide Polymorphisms (SNPs): History, Biotechnological Outlook and Practical Applications
Current Pharmacogenomics Microbial Immune Evasion Employing Suppressor of Cytokine Signaling (SOCS) Proteins
Inflammation & Allergy - Drug Targets (Discontinued) Autophagy and Crohns Disease: At the Crossroads of Infection, Inflammation, Immunity, and Cancer
Current Molecular Medicine Nucleic Acid-Based Aptamers: Applications, Development and Clinical Trials
Current Medicinal Chemistry Advances in Zebrafish High Content and High Throughput Technologies
Combinatorial Chemistry & High Throughput Screening Preparation and Antitubercular Activities of Palindromic Hydrazinecarbothioamides and Carbonothioic Dihydrazides
Letters in Drug Design & Discovery Biopharmaceutics, Pharmacokinetics and Pharmacodynamics of Antituberculosis Drugs
Current Medicinal Chemistry Cytokines in Candidiasis and Aspergillosis
Current Pharmaceutical Biotechnology Target Product Selection - Where Can Molecular Pharming Make the Difference?
Current Pharmaceutical Design Mechanistic Approach to Explore Isoniazid Derivatives as Antitubercular Agents Using KNN-MF Based-QSAR Analysis, Pharmacophore Modeling and Molecular Docking
Current Drug Therapy The Potentials of Selected Therapeutic Targets for Inflammation: A Snapshot
Recent Patents on Inflammation & Allergy Drug Discovery Molecular Docking Studies of the Antitumoral Activity and Characterization of New Chalcone
Current Topics in Medicinal Chemistry Bilayer Hydrophobic Thickness and Integral Membrane Protein Function
Current Protein & Peptide Science Prevalence of Tuberculosis in a Prison in Tehran by Active Case Finding
Infectious Disorders - Drug Targets Repositioning of DHFR Inhibitors
Current Topics in Medicinal Chemistry